These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28332143)

  • 41. Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.
    Devineni D; Polidori D
    Clin Pharmacokinet; 2015 Oct; 54(10):1027-41. PubMed ID: 26041408
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.
    Iemitsu K; Kawata T; Iizuka T; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyanagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2017 Sep; 9(9):793-801. PubMed ID: 28811858
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of serum fibroblast growth factor 21 and urinary glucose excretion in hospitalized patients with type 2 diabetes.
    Zhang R; Cai X; Du Y; Liu L; Han X; Liu W; Gong S; Zhou X; Wang X; Wen X; Ji L
    J Diabetes Complications; 2021 Jan; 35(1):107750. PubMed ID: 33097385
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Prospective, Open-Label Short-Term Pilot Study on Modification of the Skin Hydration Status During Treatment With a Sodium-Glucose Cotransporter-2 Inhibitor.
    Tezuka Y; Sekine O; Hirano A; Hanada Y; Nakanishi I; Ariga M; Azuma C; Yamamoto Y; Ito-Kobayashi J; Washiyama M; Iwanishi M; Furuta M; Kanamori M; Shimatsu A; Kashiwagi A
    Diabetes Ther; 2021 Jan; 12(1):431-440. PubMed ID: 33108650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters in Patients With Type 2 Diabetes: A Chart-Based Analysis.
    Katsuyama H; Hamasaki H; Adachi H; Moriyama S; Kawaguchi A; Sako A; Mishima S; Yanai H
    J Clin Med Res; 2016 Mar; 8(3):237-43. PubMed ID: 26858798
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessing Patient Satisfaction Following Sodium Glucose Co-Transporter 2 Inhibitor Treatment for Type 1 Diabetes Mellitus: A Prospective Study in Japan.
    Ishibashi R; Baba Y; Kakinuma K; Takasaki A; Hiraga C; Harama T; Yamamoto T; Nakamura S; Koshizaka M; Maezawa Y; Uchida D; Okajima F
    Diabetes Ther; 2021 Jan; 12(1):453-460. PubMed ID: 33237553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low dose of sodium-glucose transporter 2 inhibitor ipragliflozin attenuated renal dysfunction and interstitial fibrosis in adenine-induced chronic kidney disease in mice without diabetes.
    Yamato M; Kato N; Kakino A; Yamada KI; Inoguchi T
    Metabol Open; 2020 Sep; 7():100049. PubMed ID: 33015603
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Remogliflozin etabonate : a novel SGLT2 inhibitor for treatment of diabetes mellitus.
    Mikhail N
    Expert Opin Investig Drugs; 2015 Aug; ():1-7. PubMed ID: 26271274
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus.
    Reilly TP; Graziano MJ; Janovitz EB; Dorr TE; Fairchild C; Lee F; Chen J; Wong T; Whaley JM; Tirmenstein M
    Diabetes Ther; 2014 Jun; 5(1):73-96. PubMed ID: 24474422
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacological evaluation of HM41322, a novel SGLT1/2 dual inhibitor,
    Lee KH; Lee SD; Kim N; Suh KH; Kim YH; Sim SS
    Korean J Physiol Pharmacol; 2019 Jan; 23(1):55-62. PubMed ID: 30627010
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 1,5-anhydroglucitol is a good predictor for the treatment effect of the Sodium-Glucose cotransporter 2 inhibitor in Japanese patients with type 2 diabetes mellitus.
    Usui M; Tanaka M; Takahashi H
    J Clin Transl Endocrinol; 2020 Sep; 21():100233. PubMed ID: 32904185
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reducing HbA1c in Type 2 Diabetes Using Digital Twin Technology-Enabled Precision Nutrition: A Retrospective Analysis.
    Shamanna P; Saboo B; Damodharan S; Mohammed J; Mohamed M; Poon T; Kleinman N; Thajudeen M
    Diabetes Ther; 2020 Nov; 11(11):2703-2714. PubMed ID: 32975712
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Using a Mathematical Modeling To Simulate Pharmacokinetics and Urinary Glucose Excretion of Luseogliflozin and Explore the Role of SGLT1/2 in Renal Glucose Reabsorption.
    Wang Z; Wang G; Ren J
    ACS Omega; 2022 Dec; 7(51):48427-48437. PubMed ID: 36591124
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use.
    Goto Y; Otsuka Y; Ashida K; Nagayama A; Hasuzawa N; Iwata S; Hara K; Tsuruta M; Wada N; Motomura S; Tajiri Y; Nomura M
    Endocr Connect; 2020 Jul; 9(7):599-606. PubMed ID: 32580152
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel Indole-N-glucoside, TA-1887 As a Sodium Glucose Cotransporter 2 Inhibitor for Treatment of Type 2 Diabetes.
    Nomura S; Yamamoto Y; Matsumura Y; Ohba K; Sakamaki S; Kimata H; Nakayama K; Kuriyama C; Matsushita Y; Ueta K; Tsuda-Tsukimoto M
    ACS Med Chem Lett; 2014 Jan; 5(1):51-5. PubMed ID: 24900773
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of sodium glucose Co-transporter 2 inhibitor use on anthropometric measurements and blood glucose in obese and non-obese type 2 diabetic patients.
    Dedemen B; Duman TT; Dedemen MM; Aktas G
    Clin Nutr ESPEN; 2024 Jul; 63():515-519. PubMed ID: 39047870
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of SGLT2 Ablation or Inhibition on Corticosterone Secretion in High-Fat-Fed Mice: Exploring a Nexus with Cytokine Levels.
    Brisnovali NF; Franco I; Abdelgawwad A; Tsou HLP; Cao TH; Riva A; Rutter GA; Akalestou E
    bioRxiv; 2024 Apr; ():. PubMed ID: 38712064
    [TBL] [Abstract][Full Text] [Related]  

  • 58. There is a Close Association Between the Recovery of Liver Injury and Glycemic Control after SGLT2 Inhibitor Treatment in Japanese Subjects with Type 2 Diabetes: A Retrospective Clinical Study.
    Kinoshita T; Shimoda M; Sanada J; Fushimi Y; Hirata Y; Irie S; Obata A; Kimura T; Hirukawa H; Kohara K; Tatsumi F; Kamei S; Nakanishi S; Mune T; Kaku K; Kaneto H
    Diabetes Ther; 2018 Aug; 9(4):1569-1580. PubMed ID: 29931506
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes.
    Liu J; Chang X; Ding X; He X; Wang J; Wang G
    Diabetol Metab Syndr; 2023 Dec; 15(1):251. PubMed ID: 38044448
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sodium
    Shah CV; Robbins TS; Sparks MA
    Kidney Med; 2022 Oct; 4(10):100533. PubMed ID: 36185705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.